Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Guidelines

Which of the guidelines for use of CDK 4/6 inhibitors do you use to guide treatment for patients with HR-positive/HER2-negative early breast cancer? Credit available for this activity expires: 3/27/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990129?ecd=bdc_podcast_libsyn_mscpedu